Metabolic dysfunction-associated steatohepatitis (MASH; formerly known as non-alcoholic steatohepatitis or NASH) is a severe form of fatty liver disease. With few treatments available that improve liver damage caused by MASH, Summit Clinical Research is exploring future treatment options to potentially help patients. We’re enrolling for multiple studies, and we need people with fatty liver disease (MASH) to participate.
Study treatment.
Close care and monitoring.
Compensation.
Join Summit Clinical Research in our mission to develop treatments for fatty liver disease.
Take our prescreener to see if you may be eligible for one of our open clinical studies.